REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

NCT02233075 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic HBV Infection (HBeAg Negative)

Interventions

DRUG: REP 2139-Ca + Pegasys (TM)

Sponsor

Replicor Inc.